Trial Profile
Best Practice With Rocuronium, Neostigmine, Sugammadex, and Subjective Monitoring
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2022
Price :
$35
*
At a glance
- Drugs Neostigmine (Primary) ; Sugammadex (Primary) ; Rocuronium bromide
- Indications Neuromuscular blockade
- Focus Therapeutic Use
- 17 May 2019 Status changed from recruiting to completed.
- 12 Jun 2018 Status changed from not yet recruiting to recruiting.
- 06 Jun 2018 New trial record